Full text is available at the source.
Abstract
Sodium-glucose cotransporter 2 inhibitors may slow chronic kidney disease progression and improve cardiovascular outcomes in diabetic kidney disease.
- Diabetic kidney disease often presents with reduced kidney function and protein in the urine.
- Strict management of blood sugar and blood pressure is essential for controlling diabetic kidney disease.
- Glucagon-like peptide 1 receptor agonists are associated with reduced protein in the urine and better preservation of kidney function.
- Finerenone has been shown to lower risks related to kidney and heart health in patients with diabetic kidney disease.
- Combination therapies, including sodium-glucose cotransporter 2 inhibitors and other targeted treatments, may enhance treatment efficacy.
- Key drivers of diabetic kidney disease include increased kidney pressure, damage to kidney cells, and inflammation.
Simplified